Intercell AG

Intercell AG: Changes to the Supervisory Board

@@start.t1@@--------------------------------------------------------------------------------   ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for   the content of this announcement. --------------------------------------------------------------------------------@@end@@

Wien (euro adhoc) - Vienna (Austria), December 15, 2006 - Intercell AG (VSE, "ICLL") announced today the following realignment in its Supervisory Board:

Hans Küpper, who represented the private equity firm Global Life Science Ventures on Intercell’s Supervisory Board, resigns from his position resigned with effect of today.

The company would like to thank Hans Küpper for his good cooperation and long-term commitment to the company.

With this resignation, all venture capital firms have now left Intercell’s Supervisory Board. The Supervisory Board now includes the following members: Michel Gréco (Chairman), Ernst-Günter Afting (Vice-chairman), Staph Bakali, David Ebsworth, James Sulat and Hans Wigzell.

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unaddressed medical need.  Intercell develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Wyeth, Sanofi Pasteur S.A., Merck & Co., Inc., Kirin Brewery Co., Ltd. and the Statens Serum Institut.

Intercell has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III clinical trials, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for Tuberculosis and S. aureus, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

@@start.t2@@end of announcement                                                 euro adhoc 15.12.2006 08:14:28
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN:      AT0000612601
WKN:        A0D8HW
Börsen:  Wiener Börse AG / official market



Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: